Clinical trial
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70…
NCT00219752 · Poitiers University Hospital, Other · Completed
Key facts
| NCT number | NCT00219752 |
|---|---|
| Title | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years |
| Official title | Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase With Age More Than 70, Diagnosis of CML is Being Performed Within 1 Year |
| Lead sponsor | Poitiers University Hospital, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib mesylate 400 mg |
| Enrollment | 30 |
| Start date | May 1, 2002 |
| Completion | May 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 22, 2005 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: